7 results about "Solid cancer" patented technology

This article provides information on multi-chain chimeric peptides and their use in the treatment of unresectable, advanced, recurrent and / or metastatic solid tumors or unresectable, advanced, recurrent and / or metastatic solid cancers.

An injectable liquid containing bioactive molecules released from a powder comprising a neo-synthesized extracellular matrix for use in the treatment or prevention of cancer, in particular in the local treatment of solid tumors.

The present disclosure provides methods, compositions, uses, and kits for treatment of solid cancer (e.g., urothelial cancer (UC), head and neck squamous cell carcinoma (HNSCC), cervical cancer (CC), endometrial carcinoma (EC), or triple-negative breast cancer (TNBC)) using anti-human Nectin-4 therapeutics.

The present invention relates to the treatment of diseases associated with inflammation including solid cancers. More particularly, certain methods relate to the administration (e.g., intravenously) of polyhedrin protein (PODS) crystals for the delivery of one or more therapeutic proteins. This enables targeted release of low doses of the therapeutic protein at sites of the disease.

This invention discloses a traditional Chinese medicine composition for treating various cancers and its preparation process, belonging to the field of natural Chinese medicine anti-tumor technology. It aims to address the technical shortcomings and industry gaps of existing anti-cancer Chinese medicines, such as significant toxic side effects, limited intervention scenarios, lack of standardized medication systems, complex processes, and poor recurrence prevention. The composition of this invention consists of ten pure natural and non-toxic raw materials, including Ligusticum chuanxiong, Curcuma zedoaria, and red clover powder. The total weight of a single dose is fixed at 33g, with consistent compatibility requiring no adjustments based on syndrome differentiation. It eliminates toxic medicinal materials and chemical excipients, making it suitable for all solid cancers except leukemia. This invention features a unique three-stage standardized intervention program. This invention can inhibit cancer cell proliferation and metastasis at multiple targets, effectively prevent tumor recurrence, and simultaneously repair the body's immune system and organ damage. It exhibits no drug resistance or cumulative toxicity, possessing advantages such as safety, long-lasting efficacy, broad-spectrum compatibility, standardization, and easy mass production. It effectively fills the gap in pure natural prevention and control technology for the entire cycle of solid cancer, and has extremely high clinical application value.

Provided is a method for preventing and / or treating cancer, the method including administering to a subject a composition containing manassantin and an immune checkpoint inhibitor, or manassantin A and an epithelial growth factor receptor inhibitor, as active ingredients. The composition of the presently claimed subject matter is expected to be effectively used to suppress, through co-administration, the proliferation, metastasis, relapse, or resistance to anticancer therapy of various solid cancers.

The present invention relates to: an imaging composition comprising a fluorine-18-labeled trifluoroacetic acid; and a use thereof for diagnosing solid cancers or thyroid diseases.